Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Modeling rectal cancer to advance neoadjuvant precision therapy.

Janakiraman H, Zhu Y, Becker SA, Wang C, Cross A, Curl E, Lewin D, Hoffman BJ, Warren GW, Hill EG, Timmers C, Findlay VJ, Camp ER.

Int J Cancer. 2020 Jan 27. doi: 10.1002/ijc.32876. [Epub ahead of print]

PMID:
31989583
2.

Modeling Human Cancer-induced Cachexia.

Talbert EE, Cuitiño MC, Ladner KJ, Rajasekerea PV, Siebert M, Shakya R, Leone GW, Ostrowski MC, Paleo B, Weisleder N, Reiser PJ, Webb A, Timmers CD, Eiferman DS, Evans DC, Dillhoff ME, Schmidt CR, Guttridge DC.

Cell Rep. 2019 Aug 6;28(6):1612-1622.e4. doi: 10.1016/j.celrep.2019.07.016.

3.

Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Krook MA, Bonneville R, Chen HZ, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S.

Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). pii: a004002. doi: 10.1101/mcs.a004002. Print 2019 Aug.

4.

Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade.

Riesenberg BP, Ansa-Addo EA, Gutierrez J, Timmers CD, Liu B, Li Z.

J Immunol. 2019 Sep 1;203(5):1105-1110. doi: 10.4049/jimmunol.1900594. Epub 2019 Jul 29.

PMID:
31358658
5.

Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.

Owen DH, Williams TM, Bertino EM, Mo X, Webb A, Schweitzer C, Liu T, Roychowdhury S, Timmers CD, Otterson GA.

Lung Cancer. 2019 Aug;134:167-173. doi: 10.1016/j.lungcan.2019.06.017. Epub 2019 Jun 17.

PMID:
31319977
6.

Two Distinct E2F Transcriptional Modules Drive Cell Cycles and Differentiation.

Cuitiño MC, Pécot T, Sun D, Kladney R, Okano-Uchida T, Shinde N, Saeed R, Perez-Castro AJ, Webb A, Liu T, Bae SI, Clijsters L, Selner N, Coppola V, Timmers C, Ostrowski MC, Pagano M, Leone G.

Cell Rep. 2019 Jun 18;27(12):3547-3560.e5. doi: 10.1016/j.celrep.2019.05.004. Epub 2019 May 23.

7.

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.

Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, Timmers CD, Shah MH.

J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.

8.

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.

Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, Duggan MC, Bupathi M, Brock GN, Millis SZ, Shakya R, Timmers CD, Wakely PE Jr, Pollock RE, Chen JL.

Oncologist. 2019 Jul;24(7):989-996. doi: 10.1634/theoncologist.2019-0047. Epub 2019 Apr 24.

9.

A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.

Rudolph M, Sizemore ST, Lu Y, Teng KY, Basree MM, Reinbolt R, Timmers CD, Leone G, Ostrowski MC, Majumder S, Ramaswamy B.

Breast Cancer Res Treat. 2018 Jun;169(3):457-467. doi: 10.1007/s10549-018-4718-x. Epub 2018 Feb 20.

PMID:
29464534
10.

Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.

Reinbolt RE, Sonis S, Timmers CD, Fernández-Martínez JL, Cernea A, de Andrés-Galiana EJ, Hashemi S, Miller K, Pilarski R, Lustberg MB.

Cancer Med. 2018 Jan;7(1):240-253. doi: 10.1002/cam4.1256. Epub 2017 Nov 23.

11.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

12.

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.

Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP.

Mol Cancer Ther. 2018 Jan;17(1):17-25. doi: 10.1158/1535-7163.MCT-17-0146. Epub 2017 Oct 27.

13.

Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD, Freud AG, Blachly JS, Lucas DM, Lozanski G, Jones JA, Williams K, Oakes C, Jones D, Grever MR.

Leuk Lymphoma. 2018 Apr;59(4):1008-1011. doi: 10.1080/10428194.2017.1365853. Epub 2017 Sep 18. No abstract available.

PMID:
28918710
14.

A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.

Kaufman JM, Yamada T, Park K, Timmers CD, Amann JM, Carbone DP.

Cancer Res. 2017 Jan 1;77(1):153-163. doi: 10.1158/0008-5472.CAN-16-1639. Epub 2016 Nov 7.

15.

Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.

Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB.

Mol Cancer Ther. 2017 Feb;16(2):344-356. doi: 10.1158/1535-7163.MCT-16-0337. Epub 2016 Nov 3.

16.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.

Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X.

Sci Rep. 2016 Sep 14;6:33273. doi: 10.1038/srep33273.

17.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD.

Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.

18.

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS.

Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.

19.

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.

Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.

J Natl Cancer Inst. 2016 Feb 4;108(7). doi: 10.1093/jnci/djv437. Print 2016 Jul.

20.

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.

Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, Bekaii-Saab T.

Oncotarget. 2016 Feb 2;7(5):5306-12. doi: 10.18632/oncotarget.6632.

21.

Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency.

Araujo LH, Timmers C, Shilo K, Zhao W, Zhang J, Yu L, Natarajan TG, Miller CJ, Yilmaz AS, Liu T, Amann J, Lapa E Silva JR, Ferreira CG, Carbone DP.

PLoS One. 2015 Nov 25;10(11):e0143092. doi: 10.1371/journal.pone.0143092. eCollection 2015.

22.

Risk factors for anthracycline-associated cardiotoxicity.

Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.

23.

Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo.

Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, Park M, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G.

Genes Dev. 2015 Aug 15;29(16):1707-20. doi: 10.1101/gad.262568.115.

24.

Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.

Araujo LH, Lammers PE, Matthews-Smith V, Eisenberg R, Gonzalez A, Schwartz AG, Timmers C, Shilo K, Zhao W, Natarajan TG, Zhang J, Yilmaz AS, Liu T, Coombes K, Carbone DP.

J Thorac Oncol. 2015 Oct;10(10):1430-6. doi: 10.1097/JTO.0000000000000650.

25.

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.

Wu C, Mikhail S, Wei L, Timmers C, Tahiri S, Neal A, Walker J, El-Dika S, Blazer M, Rock J, Clark DJ, Yang X, Chen JL, Liu J, Knopp MV, Bekaii-Saab T.

Br J Cancer. 2015 Jul 14;113(2):220-5. doi: 10.1038/bjc.2015.197. Epub 2015 Jul 7.

26.

Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?

Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T.

Oncotarget. 2015 Sep 8;6(26):22206-13.

27.

Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.

Araujo LH, Timmers C, Bell EH, Shilo K, Lammers PE, Zhao W, Natarajan TG, Miller CJ, Zhang J, Yilmaz AS, Liu T, Coombes K, Amann J, Carbone DP.

J Clin Oncol. 2015 Jun 10;33(17):1966-73. doi: 10.1200/JCO.2014.59.2444. Epub 2015 Apr 27.

28.

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH.

Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18.

PMID:
25635711
29.

Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial.

Cooperstone JL, Ralston RA, Riedl KM, Haufe TC, Schweiggert RM, King SA, Timmers CD, Francis DM, Lesinski GB, Clinton SK, Schwartz SJ.

Mol Nutr Food Res. 2015 Apr;59(4):658-69. doi: 10.1002/mnfr.201400658. Epub 2015 Mar 10.

30.

Comparison of custom capture for targeted next-generation DNA sequencing.

Samorodnitsky E, Datta J, Jewell BM, Hagopian R, Miya J, Wing MR, Damodaran S, Lippus JM, Reeser JW, Bhatt D, Timmers CD, Roychowdhury S.

J Mol Diagn. 2015 Jan;17(1):64-75. doi: 10.1016/j.jmoldx.2014.09.009.

31.

CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth.

Mathsyaraja H, Thies K, Taffany DA, Deighan C, Liu T, Yu L, Fernandez SA, Shapiro C, Otero J, Timmers C, Lustberg MB, Chalmers J, Leone G, Ostrowski MC.

Oncogene. 2015 Jul;34(28):3651-61. doi: 10.1038/onc.2014.294. Epub 2014 Sep 22.

32.

Ambulant cognitive assessment using a smartphone.

Timmers C, Maeghs A, Vestjens M, Bonnemayer C, Hamers H, Blokland A.

Appl Neuropsychol Adult. 2014;21(2):136-42. doi: 10.1080/09084282.2013.778261. Epub 2013 Aug 22.

PMID:
24826507
33.

Patients with unruptured intracranial aneurysms at the waiting list for intervention: risk of rupture.

Geurts M, Timmers C, Greebe P, Algra A, Rinkel GJ.

J Neurol. 2014 Mar;261(3):575-8. doi: 10.1007/s00415-013-7238-y. Epub 2014 Jan 7.

PMID:
24395192
34.

The Joint Multivariate Modeling of Multiple Mixed Response Sources: Relating Student Performances with Feedback Behavior.

Fox JP, Entink RK, Timmers C.

Multivariate Behav Res. 2014 Jan-Feb;49(1):54-66. doi: 10.1080/00273171.2013.843441.

PMID:
26745673
35.

Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor.

van Koppen CJ, Verbost PM, van de Lagemaat R, Karstens WJ, Loozen HJ, van Achterberg TA, van Amstel MG, Brands JH, van Doornmalen EJ, Wat J, Mulder SJ, Raafs BC, Verkaik S, Hanssen RG, Timmers CM.

Biochem Pharmacol. 2013 Apr 15;85(8):1162-70. doi: 10.1016/j.bcp.2013.02.001. Epub 2013 Feb 13.

PMID:
23415902
36.

Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index.

van Lierop MJ, Alkema W, Laskewitz AJ, Dijkema R, van der Maaden HM, Smit MJ, Plate R, Conti PG, Jans CG, Timmers CM, van Boeckel CA, Lusher SJ, McGuire R, van Schaik RC, de Vlieg J, Smeets RL, Hofstra CL, Boots AM, van Duin M, Ingelse BA, Schoonen WG, Grefhorst A, van Dijk TH, Kuipers F, Dokter WH.

PLoS One. 2012;7(11):e48385. doi: 10.1371/journal.pone.0048385. Epub 2012 Nov 12.

37.

Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

van Koppen CJ, de Gooyer ME, Karstens WJ, Plate R, Conti PG, van Achterberg TA, van Amstel MG, Brands JH, Wat J, Berg RJ, Lane JR, Miltenburg AM, Timmers CM.

Br J Pharmacol. 2012 Apr;165(7):2314-24. doi: 10.1111/j.1476-5381.2011.01709.x.

38.

Contraception by induction of luteinized unruptured follicles with short-acting low molecular weight FSH receptor agonists in female animal models.

van de Lagemaat R, van Koppen CJ, Krajnc-Franken MA, Folmer BJ, van Diepen HA, Mulders SM, Timmers CM.

Reproduction. 2011 Dec;142(6):893-905. doi: 10.1530/REP-11-0234. Epub 2011 Sep 19.

PMID:
21930683
39.

Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.

van de Lagemaat R, Raafs BC, van Koppen C, Timmers CM, Mulders SM, Hanssen RG.

Endocrinology. 2011 Nov;152(11):4350-7. doi: 10.1210/en.2011-1077. Epub 2011 Sep 6.

PMID:
21896671
40.

Development of Selective LH Receptor Agonists by Heterodimerization with a FSH Receptor Antagonist.

Bonger KM, Hoogendoorn S, van Koppen CJ, Timmers CM, van der Marel GA, Overkleeft HS.

ACS Med Chem Lett. 2010 Nov 8;2(1):85-9. doi: 10.1021/ml100229v. eCollection 2011 Jan 13.

41.

The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.

Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, Sharma N, Timmers C, Chodosh LA, Leone G, Saavedra HI.

Oncogene. 2010 Sep 9;29(36):5103-12. doi: 10.1038/onc.2010.253. Epub 2010 Jun 28.

42.

Oligoproline helices as structurally defined scaffolds for oligomeric G protein-coupled receptor ligands.

Bonger KM, Kapoerchan VV, Grotenbreg GM, van Koppen CJ, Timmers CM, van der Marel GA, Overkleeft HS.

Org Biomol Chem. 2010 Apr 21;8(8):1881-4. doi: 10.1039/b923556f.

PMID:
20449493
43.

Synthesis and pharmacological evaluation of dimeric follicle-stimulating hormone receptor antagonists.

Bonger KM, Hoogendoorn S, van Koppen CJ, Timmers CM, Overkleeft HS, van der Marel GA.

ChemMedChem. 2009 Dec;4(12):2098-102. doi: 10.1002/cmdc.200900344.

PMID:
19902448
44.

Discovery of selective luteinizing hormone receptor agonists using the bivalent ligand method.

Bonger KM, van den Berg RJ, Knijnenburg AD, Heitman LH, van Koppen CJ, Timmers CM, Overkleeft HS, van der Marel GA.

ChemMedChem. 2009 Jul;4(7):1189-95. doi: 10.1002/cmdc.200900058.

PMID:
19475639
45.

Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor.

van de Lagemaat R, Timmers CM, Kelder J, van Koppen C, Mosselman S, Hanssen RG.

Hum Reprod. 2009 Mar;24(3):640-8. doi: 10.1093/humrep/den412. Epub 2008 Dec 16.

PMID:
19088107
46.

Mouse development with a single E2F activator.

Tsai SY, Opavsky R, Sharma N, Wu L, Naidu S, Nolan E, Feria-Arias E, Timmers C, Opavska J, de Bruin A, Chong JL, Trikha P, Fernandez SA, Stromberg P, Rosol TJ, Leone G.

Nature. 2008 Aug 28;454(7208):1137-41. doi: 10.1038/nature07066. Epub 2008 Jun 25.

47.

A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor.

van Koppen CJ, Zaman GJ, Timmers CM, Kelder J, Mosselman S, van de Lagemaat R, Smit MJ, Hanssen RG.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):503-14. doi: 10.1007/s00210-008-0318-3. Epub 2008 Jun 13.

PMID:
18551279
48.

Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core.

Bonger KM, van den Berg RJ, Knijnenburg AD, Heitman LH, Ijzerman AP, Oosterom J, Timmers CM, Overkleeft HS, van der Marel GA.

Bioorg Med Chem. 2008 Apr 1;16(7):3744-58. doi: 10.1016/j.bmc.2008.01.054. Epub 2008 Feb 2.

PMID:
18282756
49.

[3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor.

Heitman LH, Oosterom J, Bonger KM, Timmers CM, Wiegerinck PH, Ijzerman AP.

Mol Pharmacol. 2008 Feb;73(2):518-24. Epub 2007 Nov 7.

PMID:
17989351
50.

Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.

Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers CM, van Staveren CJ.

Arthritis Res Ther. 2007;9(4):R71.

Supplemental Content

Loading ...
Support Center